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Abstract
Background and Objectives
We investigated the relationship of the Syntax Score (SS) and coronary artery calcification
(CAC), with plasma levels of biomarkers related to cardiovascular damage and mineral
metabolism, as there is sparse information in this field.
Methods
We studied 270 patients with coronary disease that had an acute coronary syndrome (ACS)
six months before. Calcidiol, fibroblast growth factor-23, parathormone, phosphate and
monocyte chemoattractant protein-1 [MCP-1], high-sensitivity C-reactive protein, galectin-
3, and N-terminal pro-brain natriuretic peptide [NT-proBNP] levels, among other biomark-
ers, were determined. CAC was assessed by coronary angiogram as low-grade (0–1) and
high-grade (2–3) calcification, measured with a semiquantitative scale ranging from 0
(none) to 3 (severe). For the SS study patients were divided in SS<14 and SS14. Multivar-
iate linear and logistic regression analyses were performed.
Results
MCP-1 predicted independently the SS (RC = 1.73 [95%CI = 0.08–3.39]; p = 0.040), along
with NT-proBNP (RC = 0.17 [95%CI = 0.05–0.28]; p = 0.004), male sex (RC = 4.15 [95%CI =
1.47–6.83]; p = 0.003), age (RC = 0.13 [95%CI = 0.02–0.24]; p = 0.020), hypertension (RC =
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3.64, [95%CI = 0.77–6.50]; p = 0.013), hyperlipidemia (RC = 2.78, [95%CI = 0.28–5.29]; p =
0.030), and statins (RC = 6.12 [95%CI = 1.28–10.96]; p = 0.013). Low calcidiol predicted
high-grade calcification independently (OR = 0.57 [95% CI = 0.36–0.90]; p = 0.013) along
with ST-elevation myocardial infarction (OR = 0.38 [95%CI = 0.19–0.78]; p = 0.006), diabetes
(OR = 2.35 [95%CI = 1.11–4.98]; p = 0.028) and age (OR = 1.37 [95%CI = 1.18–1.59];
p<0.001). During follow-up (1.79 [0.94–2.86] years), 27 patients developed ACS, stroke, or
transient ischemic attack. A combined score using SS and CAC predicted independently the
development of the outcome.
Conclusions
MCP-1 and NT-proBNP are independent predictors of SS, while low calcidiol plasma levels
are associated with CAC. More studies are needed to confirm these data.
Introduction
Increased plasma levels of inflammatory biomarkers have been associated with the develop-
ment of cardiovascular events. In addition to high-sensitivity C-reactive protein [1], enhanced
Monocyte Chemoattractant Protein-1 (MCP-1) plasma levels have been related with adverse
outcomes in patients with coronary artery disease (CAD) [2]. Other biomarkers such as galec-
tin-3 and N-terminal fragment of brain natriuretic peptide (NT-proBNP), have demonstrated
to be independent predictors of the development of heart failure and death [2–5]
In addition, low vitamin D plasma levels have been independently associated with coronary
artery calcification (CAC), atherosclerosis burden, stroke, hypertension, cardiovascular events,
and death [6–8]. Furthermore, other components of mineral metabolism are also associated
with an enhanced cardiovascular risk [9]. In this regard, increased fibroblast growth-23 (FGF-
23), parathormone (PTH) and phosphate plasma levels have been related with cardiovascular
damage [10–15].
The SYNTAX score (SS), was developed as a tool to assess the complexity of coronary lesions
in the SYNTAX (Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac
Surgery) study [16–18]. Later, this score was seen also to correlate with clinical outcomes [19].
We have investigated the relationship of the SS and the presence of CAC with plasma levels
of the components of mineral metabolism and several biomarkers related to cardiovascular
damage such as: MCP-1, neutrophil gelatinase-associated lipocalin (NGAL), and soluble
tumor necrosis factor-like weak inducer of apoptosis (sTWEAK), involved in inflammation
and atherothrombosis [20–24]; galectin-3, related to thrombosis and heart failure [3,25]; and
the inactive N-terminal fragment of brain natriuretic peptide (NT-proBNP), related mainly to
heart failure [4,5]. High-sensitivity C-reactive protein (hs-CRP) was studied as a reference,
given the important amount of information published with this biomarker. In addition, we
have assessed the prognostic value of a score combining SS and CAC.
Methods
Patients and Study Design
The research protocol complies with the Declaration of Helsinki and was approved by the eth-
ics committees of the participant hospitals. The Ethics Committee for Clinical Research of the
Universitary Hospital Fundacion Jimenez Diaz, approved the study. All patients signed
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informed consent documents. The Biomarkers in Acute Coronary Syndrome (BACS) and Bio-
markers in Acute Myocardial Infarction (BAMI) studies, included patients admitted at four
hospitals in the area of Madrid with either non-ST elevation acute coronary syndrome
(NSTEACS) or ST elevation myocardial infarction (STEMI). Detailed inclusion and exclusion
criteria have been reported previously [2]. The present paper analyzes data from patients
included in the BACS and BAMI studies at one of the four participant hospitals.
Between July 2006 and April 2010, 676 patients were discharged from Fundación Jiménez
Díaz with a diagnosis of NSTEACS or STEMI. Of them, 284 were included in the BACS-BAMI
studies. The remaining patients were not included due to: age over 85 years (16.3%), presence
of disorders or toxic habits limiting survival (35.8%), impossibility to perform cardiac revascu-
larization (13.5%), coexistence of other significant cardiopathy (5.8%), impossibility to perform
follow-up (12.0%), clinical instability beyond the 6th day at the index event (10.1%), refusal to
participate in the study (0.9%), death before the second visit (0.3%), and impossibility of the
investigators to include them (5.3%). Finally, 14 patients had not coronary angiogram avail-
able, leading 270 patients for analysis.
Patients were seen six months later, on an outpatient basis. Plasma was withdrawn and a
complete set of clinical variables was recorded. This study reports clinical and analytical find-
ings obtained at this outpatient visit relating them to subsequent follow-up.
Laboratory Determinations
The investigators who performed the analytical studies were unaware of clinical data.
Plasma concentrations of MCP-1, galectin-3, sTWEAK, and NGAL were determined in
duplicate using commercially available enzyme-linked immunosorbent assay kits (BMS279/2,
BenderMedSystems, Burlingame, California; DCP00, R&D Systems, Minneapolis, Minnesota;
BMS2006INST, Bender MedSystems, Burlingame, California; and Kit 036, BioPorto, Gentofte,
Denmark, respectively) following the manufacturers’ instructions. Intra- and interassay coeffi-
cients of variation were 4.6% and 5.9% for MCP-1, 6.2% and 8.3% for galectin-3, 6.1% and
8.1% for sTWEAK, and 5.3% and 7.9% for NGAL, respectively. High-sensitivity C-reactive
protein was assessed by latex-enhanced immunoturbidimetry (ADVIA 2400 Chemistry Sys-
tem; Siemens, Munich, Germany) and NT-proBNP by immunoassay (VITROS; Ortho Clinical
Diagnostics Raritan, New Jersey). Lipid, glucose, and creatinine levels were determined by stan-
dard methods (ADVIA 2400 Chemistry System; Siemens).
Plasma levels of calcidiol (a vitamin D metabolite) were quantified by chemiluminescent
immunoassay (CLIA) on the LIAISON XL analyzer (LIAISON 25OH-Vitamin D total Assay
DiaSorin, Saluggia, Italy), FGF-23 was measured by an enzyme-linked immunosorbent assay
which recognizes epitopes within the carboxyl-terminal portion of FGF- 23 (Human FGF-23,
C-Term, Immutopics Inc, San Clemente, CA), intact PTH was analyzed by a second-genera-
tion automated chemiluminescent method (Elecsys 2010 platform, Roche Diagnostics, Mann-
heim, Germany) and phosphate was determined by an enzymatic method (Integra 400
analyzer, Roche Diagnostics, Mannheim, Germany).
Assessment of Syntax Score and Coronary Calcium
SS and CAC were assessed by two interventional cardiologists. SS was calculated using the SS
web calculator version 2.11 and CAC was classified from 0 to 3 using a scale where 0 was
absence of CAC, 1 mild (radiopacities noted only during the cardiac cycle before contrast injec-
tion after carefully examination), 2 moderate (evident radiopacities noted only during the car-
diac cycle before contrast injection), and severe (radiopacities noted without cardiac motion
before contrast injection generally compromising both sides of the arterial lumen), [26].
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To simplify the analysis, a binary calcification (BC) variable (low [0–1] and high [2–3]
grade calcification) was created and Kappa coefficient was performed to assess the inter-
observer agreement. Finally, to assess the prognostic value of CAC and SS a score combining
these two variables was designed. Patients were divided in three groups: Group 0 (SS below the
median of global cohort and BC 0–1), Group 1 (SS above or equal the median or BC 2–3) and
Group 2 (SS above or equal the median and BC 2–3).
Definition of Events
Patients were considered to present hypertension if they had a history of systolic and/or dia-
stolic pressure equal to or higher than 140 and 90 mmHg, respectively or if they were taking
blood-pressure-lowering drugs for this disorder. Patients with current or past tobacco use were
considered smokers. Patients receiving lipid-lowering therapy for this diagnosis and those with
fasting lipid levels [LDL cholesterol>160 mg/dl and/or triglyceride levels>200 mg/dl] were
considered to be diagnosed with dyslipidemia. Finally, patients were considered to be diabetics
if they were receiving therapy for the disease or if they had fasting glucose levels> 126 mg/dl.
After the outpatient visit, patients were followed recording the incidence of the outcome
composed of NSTEACS, STEMI, and stroke/transient ischemic attack, defined as described
previously [2].
Statistical methods
Quantitative data following a normal distribution are presented as mean +/- SD and compared
using the Student t-test or ANalysis Of VAriance (ANOVA). Those not normally distributed
are displayed as median (interquartile range) and compared using the Mann-Whitney test.
Qualitative variables are displayed as percentages and compared using chi-square or Fisher’s
exact test when appropriate.
All variables were analyzed by linear regression taking the presence of SS as dependent vari-
able, and by binary logistic regression taking CAC as dependent variable. Thereafter, we con-
structed a multivariate model including all variables that had a level of significance p<0.2 at
univariate analyses. The final model included all variables with p<0.05.
Survival-free of outcome curves were traced with the Kaplan-Maier method and groups
were compared with the log-rank test. Cox proportional hazards model was used with forward
stepwise selection to assess the variables associated with the outcome. All the variables with
p<0.2 were included into the multivariate model. This multivariate analysis was done with the
backward step method.
Analyses were performed with SPSS 19.0 (SPSS Inc., New York), and were considered sig-
nificant when p<0.05 (two-tailed).
Results
Baseline characteristics, clinical variables and plasma biomarkers levels are listed in Table 1.
Stratification by age showed that MCP-1, Galectin-3, NT-proBN,P NGAL, and PTH plasma
levels increased along with age (S1 Table). Women were older than men [(71.5 (59.0–80.0) vs
62.0 (52.2–74.7) years; p<0.001)] and had higher plasma levels of Galectin-3, PTH, and phos-
phate (S1 Table).
Biomarkers associated with a high Syntax Score
Median SS was 14 (7–23). There were 198 cases with a SS 0–22, 50 with 23–32 and 22 with33.
For descriptive purposes we divided the total population into two similar groups according to
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Table 1. Baseline characteristics, clinical variables and plasma biomarkers levels.
Variable Total population
(N = 270)
SS (<14)131
patients
SS (14)139
patients
p
value
BC (0–1)219
patients
BC (2–3)51
patients
p
value
Age (yrs) 65.0 (54.0–76.0) 63.0 (51.0–73.0) 71.0 (58.0–78.0) <0.001 63.0 (52.0–75.0) 76 (62.0–81.0) <0.001
Men 180 (66.7%) 79 (60.3%) 101 (72.7%) 0.031 150 (68.5%) 30 (58.8%) 0.193
Body mass index (kg/m2) 27.9 (25.5–30.9) 28.2 (25.7–31.6) 27.7 (25.0–30.1) 0.345 28.1 (25.6–31.0) 27.3 (24.2–30.0) 0.283
Diabetes mellitus 56 (20.7%) 22 (16.8%) 34 (24.5%) 0.119 40 (18.3%) 16 (31.4%) 0.045
Smoker (present or former) 186 (68.9%) 91 (69.5%) 95 (68.3%) 0.842 155 (70.8%) 31 (60.8%) 0.172
Hypertension 189 (70%) 80 (61.1%) 109 (78.4%) 0.002 148 (67.6%) 41 (80.4%) 0.063
Dyslipidemia 135 (50%) 61 (46.6%) 74 (53.2%) 0.273 111 (50.7%) 24 (47.1%) 0.641
Peripheral artery disease 4 (1.5%) 0 (0%) 4 (2.9%) 0.123 1 (0.5%) 3 (5.9%) 0.022
Cerebrovascular events 15 (5.6%) 4 (3.1%) 11 (7.9%) 0.075 10 (4.6%) 5 (9.8%) 0.170
Atrial ﬁbrillation 17 (6.3%) 8 (6.1%) 9 (6.5%) 0.901 13 (5.9%) 4 (7.8%) 0.537
LV ejection fraction <40% 60.0% (50.0–67.0) 60.0% (52.0–69.0) 59.0% (45.0–65.5) 0.013 60.0 (50.0–68.0) 60.0 (45.0–66.0) 0.557
ASA 246 (91.1%) 123 (93.9%) 123 (88.5%) 0.115 202 (92.2%) 44 (86.3%) 0.179
Clopidogrel 202 (74.8%) 95 (72.5%) 107 (77.0%) 0.399 163 (74.4%) 39 (76.5%) 0.761
Acenocumarol 16 (5.9%) 6 (4.6%) 10 (7.2%) 0.360 13 (5.9%) 3 (5.9%) 1.000
Statins 251 (93%) 120 (91.6%) 131 (94.2%) 0.396 202 (92.2%) 49 (96.1%) 0.543
ACEI 187 (69.3%) 93 (71.0%) 94 (67.6%) 0.549 157 (71.7%) 30 (58.8%) 0.079
ARB 57 (21.1%) 23 (17.6%) 34 (24.5%) 0.164 46 (21.0%) 11 (21.6%) 0.929
β-Blockers 191 (70.7%) 90 (68.7%) 101 (72.7%) 0.475 154 (70.3%) 37 (72.5%) 0.751
STEMI* 126 (46.7%) 59 (45.0%) 67 (48.2%) 0.603 111 (50.7%) 15 (29.4%) 0.005
SYNTAX score* 14.0 (7.0–23.0) 6.5 (3.0–10.0) 23.0 (17.5–28.0) <0.001 12.0 (6.0–21.5) 22.0 (16.0–33.0) <0.001
BC (0–1) %/ BC (2–3) % 81.1/18.9 93.1/6.9 69.8/30.2 <0.001 ---------------------------- --------------------------- ----------
Complete
revascularization*
189 (70%) 107 (81.7%) 82 (59.0%) <0.001 160 (73.1%) 29 (56.9%) 0.027
LDL cholesterol (mg/dl) 75.5 (61.0–94.0) 77.0 (64.0–95.0) 74.0 (59.0–93.0) 0.338 76.0 (61.0–93.0) 74.0 (61.0–101.0) 0.862
HDL cholesterol (mg/dl) 44.0 (36.0–51.0) 45.0 (36.0–56.0) 43.0 (37.0–47.0) 0.077 44.0 (36.0–51.0) 44.0 (38.0–50.0) 0.575
Triglycerides (mg/dl) 102.0 (74.7–139.2) 97.0 (75.0–132.0) 107.0 (74.0–150.0) 0.238 101.0 (76.0–142.0) 109.0 (65.0–138.0) 0.666
eGFR (ml/min/1.73 m2) 75.2 (60.1–87.4) 80.3 (65.3–91.7) 70.0 (56.0–83.1) <0.001 76.7 (62.3–89.9) 66.4 (51.1–82.0) 0.010
hsCRP (mg/L) 1.7 (0.7–3.7) 1.6 (0.6–3.4) 1.8 (0.8–4.1) 0.271 1.8 (0.7–3.8) 1.4 (0.7–3.6) 0.601
MCP-1 (pg/ml) 142.4 (112.2–179.2) 130.5 (109.0–165.6) 153.7 (119.8–188.1) 0.001 137.0 (110.1–176.5) 165.6 (128.1–
197.0)
0.005
Galectin-3 (ng/ml) 8.6 (7.2–10.0) 8.3 (7.2–9.7) 8.7 (7.2–10.6) 0.058 8.4 (7.0–9.8) 9.0 (7.5–10.5) 0.078
NT-proBNP (pg/ml) 209.5 (99.5–521.0) 151.0 (85.4–289.0) 343.0 (125.0–848.0) <0.001 167.0 (88.7–450.0) 387 (176.0–860.0) 0.001
NGAL (ng/ml) 165.2 (127.3–219.2) 153.9 (119.5–202.6) 178.4 (131.0–238.8) 0.002 156.5 (121.7–213.8) 195.9 (161.5–
247.6)
0.002
sTWEAK (pg/ml) 198.0 (159.4–249.2) 200.3 (160.9–267.2) 196.7 (156.2–244.7) 0.245 201.5 (157.3–264.8) 193.7 (167.8–
228.8)
0.283
PTH (pg/ml) 65.1 (49.5–84.2) 60.8 (47.4–81.1) 68.7 (51.1–90.9) 0.039 63.3 (48.9–82.5) 71.7 (51.3–96.0) 0.037
Phosphate (mg/dl) 3.3 (2.9–3.6) 3.3 (3.0–3.7) 3.2 (2.8–3.6) 0.133 3.2 (2.9–3.6) 3.3 (3.0–3.7) 0.317
AP (UI/l) 75 (61.5–92.5) 76 (62.7–93) 74 (61–92) 0.747 74 (61–92) 79 (64–96) 0.544
FGF-23 (RU/ml) 68.1 (54.4–88.8) 67.0 (54.7–86.8) 69.3 (54.4–92.9) 0.650 67.0 (52.3–87.2) 72.0 (13.0–25.8) 0.124
Calcidiol (ng/ml) 18.4 (12.5–24.9) 18.8 (13.0–25.8) 16.5 (11.7–24.0) 0.134 18.8 (13.0–25.8) 14.6 (10.2–20.9) 0.007
Quantitative data following a normal distribution are presented as mean (standard deviation [SD]) and those not normally distributed are displayed as
median (interquartile range). LV: left ventricle, ASA: Acetylsalicylic acid, ACEI: Angiotensin-converting enzyme inhibitors, ARB: Angiotensin-receptor
blockers, STEMI: ST-elevation myocardial infarction, BC: Binary Calciﬁcation, LDL: Low-density lipoprotein, HDL: High-density lipoprotein. eGFR:
Glomerular Filtration Rate as estimated by CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration), Hs-CRP: High-sensitivity C-reactive protein,
MCP-1: Monocyte chemoattractant protein-1. NGAL: Neutrophil gelatinase-associated lipocalin. sTWEAK: Soluble tumor necrosis factor-like weak inducer
of apoptosis, PTH: Parathormone, AP: Alkaline Phosphatase. FGF-23: Fibroblast growth factor-23.
* Data related to the previous acute coronary syndrome
doi:10.1371/journal.pone.0152816.t001
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the median: SS<14 (131 patients) and SS14 (139 patients). S2 Table shows the results of the
univariate analysis.
At multivariate regression analysis (Table 2), MCP-1 was an independent predictor of SS
(RC [Regression Coefficient] = 1.73 for each increase of 50 pg/mL, [95%CI = 0.08–3.39];
p = 0.040) along with NT-proBNP (RC = 0.17 for each increase of 100 pg/mL, [95% CI = 0.05–
0.28]; p = 0.004), male sex (RC = 4.15 [95%CI = 1.47–6.83]; p = 0.003), age (RC = 0.13 for each
increase of 5 years, [95%CI = 0.02–0.24]; p = 0.020), hypertension (RC = 3.64 [95%CI = 0.77–
6.50]; p = 0.013), hyperlipidemia (RC = 2.78 [95%CI = 0.28–5.29]; p = 0.030) and statins
(RC = 6.12 [95%CI = 1.28–10.96]; p = 0.013).
Predictors of coronary calcification
Fifty-one patients (18.9%) had high grade BC (2–3). The kappa coefficient for inter-observer
agreement was 0.783. S3 Table displays the results of the univariate logistic regression analysis.
At multivariate regression analysis (Table 2), calcidiol was the only biomarker that was
shown to be an independent predictor of BC (OR [Odds Ratio] = 0.57 for each increase of 10
ng/mL, [95%CI = 0.36–0.90]; p = 0.013). Other independent predictors were STEMI
(OR = 0.38,[95%CI = 0.19–0.78]; p = 0.006), diabetes (OR = 2.35, [95%CI = 1.11–4.98];
p = 0.028) and age (OR = 1.37 for each increase of 5 years, [95%CI = 1.18–1.59]; p<0.001).
Prognostic Value of a combined SS and calcium score
Patients were divided in three groups according to a combined score including SS and BC, as
explained previously. The distribution of clinical variables across the different subgroups is
shown in Table 3.
During a median follow-up of 1.79 (0.94–2.86) years, a total of 27 patients reached the out-
come. Group 0 (122 patients): 8 events (6.6%), Group 1 (106 patients): 9 events (8.5%), and
Table 2. Multivariate regression analysis showing the variables independently associated with SS
and CAC.
SS as dependent variable Regression Coefﬁcient 95% CI Lower Upper P
Age (yrs)* 0.13 0.02 0.24 0.020
Men 4.15 1.47 6.83 0.003
Hypertension 3.64 0.77 6.50 0.013
Hyperlipidemia 2.78 0.28 5.29 0.030
MCP-1** 1.73 0.08 3.39 0.040
NT-ProBNP*** 0.17 0.05 0.28 0.004
Statins 6.12 1.28 10.96 0.013
CAC as dependent variable Odds Ratio 95% CI Lower Upper P
Age (yrs)* 1.37 1.18 1.59 <0.001
Diabetes Mellitus 2.35 1.11 4.98 0.028
STEMI 0.38 0.19 0.78 0.006
Calcidiol**** 0.57 0.36 0.90 0.013
Abbreviations: SS: Syntax Score, CAC: Coronary artery calciﬁcation, CI: Conﬁdence interval, other
abbreviations as for Table 1.
* Age: RC or OR for each increase of 5 years.
** MCP-1: RC for each increase of 50 pg/mL.
*** NT-proBNP: RC for each increase of 100 pg/mL.
****Calcidiol: OR for each increase of 10 ng/mL.
doi:10.1371/journal.pone.0152816.t002
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Group 2 (42 patients): 10 events: (23.8%). Kaplan-Maier curves show that patients from group
2 had a lower event-free survival (p = 0.001) (Fig 1) than the other two groups.
S4 Table displays the results of the univariate Cox regression analysis.
At multivariate analysis, we found that the only independent predictors were the combined
variable of SS and CC (HR [Hazard Ratio] (group 2 vs. group 0) = 4.83 [95%CI = 1.90–12.27];
p = 0.001; HR (group 1 vs. group 0) = 1.35 [95%CI = 0.51–3.62]; p = 0.549; HR (group 2 vs.
group 1) = 3.57 [95%CI = 1.40–9.08]; p = 0.008) and body-mass index (HR = 1.08 [95%
CI = 1.01–1.15] for each increase of 1 kg/m2, p = 0.041). None of the biomarkers studied in our
work were found to be independent predictors of outcomes.
Discussion
MCP-1 and NT-proBNP as predictors of the complexity of CAD
The SS is a scoring system that ranks the complexity of the coronary anatomy and is useful to
make decisions regarding coronary revascularization [16,18,27], having also prognostic ability
[18,19,28]. This makes sense, as the SS takes into account the number, extension, and severity
of lesions, and the existence of thrombus or collateral vessels and if the lesion is located in tor-
tuous vessel areas [27]. Then, it adds a lot of characteristics to the simple definition of the num-
ber of diseased vessels that are related with the severity of CAD, and with the probability of
receiving an adequate revascularization.
In our paper we demonstrate, for the first time, that high MCP-1 levels predict indepen-
dently the existence of a high SS. This is a chemokine that plays a key role in the recruitment of
Table 3. Distribution of clinical variables across the different subgroups according to the combined
Syntax Score and Calcium Score.
Variable Total
population
(N = 270)
Group 0 (SS<14
and BC 0–1)
(N = 122)
Group 1 (SS
14 or BC 2–3)
(N = 106)
Group 2 (SS
14 and BC
2–3)(N = 42)
P
value
Age (yrs) 65.0 (54.0–
76.0)
62 (51–73) 66.5 (55–77) 76.5 (65–81) 0.001
Men 66.7% 60.7% 76.4% 59.5% 0.441
Body mass index
(kg/m2)
27.9 (25.5–
30.9)
28.5 (25.8–31.7) 27.7 (25.1–30.2) 27.7 (24.6–30.1) 0.352
Diabetes mellitus 20.7% 15.6% 22.6% 31% 0.028
Smoker (present or
former)
68.9% 70.5% 69.8% 61.9% 0.375
Hypertension 70% 59% 79.1% 78.6% 0.002
LV ejection fraction
<40%
60.0% (50.0–
67.0)
60.0% (52.0–
70.0)
57.0% (46.0–64) 60% (45–67) 0.017
ASA 91.1% 95.9% 85.8% 90.5% 0.025
Clopidogrel 74.8% 71.3% 79.2% 73.8% 0.383
Acenocumarol 5.9% 7.9% 6.6% 7.1% 0.811
Statins 93% 91.8% 92.5% 97.6% 0.351
β-Blockers 70.7% 68.9% 71.7% 73.8% 0.802
STEMI 46.7% 45.1% 56.6% 26.2% 0.030
Complete
revascularization
70% 81.1% 65.1% 50% 0.001
eGFR (ml/min/1.73
m2)
75.2 (60.1–
87.4)
80.5 (66.6–91.8) 71.9 (57.4–85.2) 66.3 (52.2–80.5) 0.001
Abbreviations, as for Table 1.
doi:10.1371/journal.pone.0152816.t003
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monocytes into the vascular wall during atherogenesis [20,21]. In fact, we have demonstrated
that drugs that interfere with the progression of atherosclerosis, such as statins and angioten-
sin-converting enzyme inhibitors, decrease the expression of this chemokine [29,30]. Even
more, MCP-1 may have procoagulant properties [31]. In accordance with this, MCP-1 plasma
levels predict the risk of cardiovascular events in patients with stable CAD [2] and acute coro-
nary syndrome [32,33]. Therefore, the ability of MCP-1 to predict the complexity of CAD fits
with its known properties.
On the other hand, increased NT-proBNP plasma levels were also independent predictors
of a high SS, even after controlling for the existence of important left ventricular dysfunction in
the multivariate analysis. In this case, the potential mechanism of this association is not clear.
However, NT-proBNP may have unexpected roles. In this regard, although initially described
in the brain, it is now known to be secreted by the ventricular myocardium [5], and it is being
used for the diagnosis of heart failure [4,5], having also prognostic value in patients with car-
diovascular disease [2]. More recently, NT-proBNP levels have been shown to increase in
patients with cancer [34–37]. Given that natriuretic peptides have been shown to have antipro-
liferative effects [38–40] it has been hypothesized that NT-proBNP plasma levels could increase
in response to the excessive cell proliferation present in cancer [37]. Then, the possibility exists
that NT-proBNP plasma levels could also increase in response to the cell proliferation present
in atherosclerosis, and that theoretically should be especially important in cases of extensive
and severe CAD. Nevertheless, more research is needed to elucidate the link between natri-
uretic peptides and the existence of a high SS.
Fig 1. Kaplan-Meier curves showing time to outcome according to the combined syntax and calcium
score.
doi:10.1371/journal.pone.0152816.g001
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Finally, there was a positive association between statin therapy and SS. However, this was an
observational study and the therapy with statins recorded reflects the treatment given to the
patients after the coronary angiogram, not in the previous years where the complexity of CAD
was established. Thus, we estimated that this fact simply suggests that patients with more
severe CAD were receiving statins more often.
Low levels of calcidiol predict the existence of high-grade calcification in
CAD
CAC is known as sub-clinical atherosclerosis, and has prognostic implications [41]. Moreover,
severe CAC limits stent expansion, a fact that can be associated with restenosis and stent
thrombosis [42].
In the last years there has been growing interest in the relationship of mineral metabolism
with cardiovascular disease. Classically, mineral metabolism has been related to chronic kidney
disease. In this regard, when kidneys begin to fail, phosphate excretion decreases, and increased
phosphatemia may be associated to cardiovascular damage [13]. To compensate this, there is
an increase in plasma levels of FGF-23 and PTH, which promote phosphaturia [10]. However,
enhanced FGF-23 and PTH levels may also favor vascular damage, and left ventricular hyper-
trophy [10–15]. In addition, FGF-23 decreases vitamin D availability by both increasing its
catabolism and diminishing its synthesis [10]. Low levels of vitamin D may lead to endothelial
dysfunction, inflammation, activation of the renin-angiotensin system, vascular smooth muscle
cell proliferation and CAC [6–14,43–45]. In accordance with this, low vitamin D levels have
been associated with a high risk of cardiovascular disease and cardiovascular death in patients
with and without cardiovascular disease at baseline [15,46–48].
Although low vitamin D levels are characteristic of chronic kidney disease, we have
described recently that more than 50% of patients with CAD present low levels of calcidiol, a
metabolite of vitamin D, in the presence of average estimated glomerular filtration rate [15].
Even more, low calcidiol levels and other abnormalities of mineral metabolism were evident in
the presence of mild decreases in estimated glomerular filtration rate.
In our study, low calcidiol levels were independently associated with high grade CAC. This
could play an important role in the higher incidence of adverse outcomes seen in patients with
low calcidiol levels. Accordingly, Watson et al found an inverse relationship between 1,25-vita-
min D plasma levels and CAC [7]. However, they studied patients at high risk of CAD in pri-
mary prevention. We have confirmed these findings in patients with CAD. Moreover, we
performed a complete study of mineral metabolism including FGF-23, PTH, alkaline phospha-
tase, and phosphate plasma levels. Interestingly, the inverse association between vitamin D and
CAC was evident despite controlling for levels of all these molecules. This suggests that vitamin
D may have a beneficial effect on the process of coronary calcification that may be independent
of other abnormalities of mineral metabolism.
Prognostic value of a score combining CAC and SS
The SS and CAC are two variables related with the extent and severity of the CAD. Even more,
they have been shown to predict clinical events [19,28,41]. Our study suggests that a scale com-
bining SS and BC outperforms these isolated scores. Of interest, this finding was obtained after
controlling for a large set of clinical variables and more important, biomarkers that have been
shown previously to have a good prognostic value, such as MCP-1 and NT-proBNP [2,32,33].
Thus, this finding should be tested in future studies involving larger populations as these bio-
markers could be acting as surrogates of the coronary anatomy complexity. So, it could be
more effective to use this score than performing biomarker determinations.
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Limitations
Plasma determination was performed six months after coronary angiogram was carried out.
Nevertheless, the development of CAC and of complex coronary lesions is a chronic process.
Analyzing data in the setting of the previous acute coronary syndromes, could have given con-
founding results, as biomarker levels may change in the acute episode. Thus, studying biomark-
ers with the patients in a stable situation may give a more accurate idea of their chronic levels.
The therapy used in these patients could theoretically influence levels of the biomarkers stud-
ied. However, we have taken this into account in our analyses, and there was no influence of
the treatment used.
Finally, given the limited sample size and number of events, these results should be con-
firmed in future studies.
Conclusions
Increased MCP-1 and NT-proBNP plasma levels are independently associated with high SS. In
addition, low calcidiol levels are related to high grade CAC, even when other components of
mineral metabolism are taken into account. Although the relationship between inflammation
and atherosclerosis is clear, more work is needed to ascertain the cause of the possible relation-
ship of NT-proBNP with a high SS. Finally, a score combining CAC and SS, but not the bio-
markers studied, has independent prognostic value. Thus, coronary anatomy should be taken
in consideration in future biomarkers studies to rule out the possibility that the predictive
value of these molecules could be a surrogate of the existence of complex coronary lesions.
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